Baseline characteristics
| Characteristics . | Full analysis set . |
|---|---|
| All patients of the full analysis set, N | 40 |
| Sex, N (%) | 40 |
| Female, n (%) | 13 (32.5) |
| Male, n (%) | 27 (67.5) |
| Age, y | 40 |
| Median (range) | 64 (40-82) |
| Time since first diagnosis, mo | 40 |
| Median (range) | 103.5 (42.2-240.2) |
| Binet stage, N (%) | 40 |
| A, n (%) | 11 (27.5) |
| B, n (%) | 19 (47.5) |
| C, n (%) | 10 (25.0) |
| Total CIRS score | 40 |
| Median (range) | 3 (0-12) |
| Creatinine clearance (mL/min) | 40 |
| Median (range) | 82.1 (35.6-153.1) |
| del(17p), N (%) | 40 |
| Yes, n (%) | 5 (12.5) |
| del(11q), N (%) | 40 |
| Yes, n (%) | 15 (37.5) |
| Trisomy 12, N (%) | 40 |
| Yes, n (%) | 3 (7.5) |
| del(13q), N (%) | 40 |
| Yes, n (%) | 23 (57.5) |
| Type according to hierarchical model, N (%) | 40 |
| del(17p), n (%) | 5 (12.5) |
| del(11q), n (%) | 15 (37.5) |
| Trisomy 12, n (%) | 1 (2.5) |
| Not del(17p)/del(11q)/trisomy 12/del(13q), n (%) | 9 (22.5) |
| del(13q) alone, n (%) | 10 (25.0) |
| IGHV mutational status, N (%) | 40 |
| Unmutated, n (%) | 31 (77.5) |
| Mutated, n (%) | 9 (22.5) |
| TP53 mutational status, N (%) | 40 |
| Unmutated, n (%) | 26 (65.0) |
| Mutated, n (%) | 14 (35.0) |
| TP53 status, N (%) | 40 |
| None, n (%) | 25 (62.5) |
| Deleted and/or mutated, n (%) | 15 (37.5) |
| NOTCH1 mutational status, N (%) | 40 |
| Unmutated, n (%) | 30 (75.0) |
| Mutated, n (%) | 10 (25.0) |
| SF3B1 mutational status, N (%) | 40 |
| Unmutated, n (%) | 27 (67.5) |
| Mutated, n (%) | 13 (32.5) |
| Serum β2-microglobulin (mg/dL) | 39 |
| Median (range) | 4.5 (2.1-17.2) |
| Complex karyotype, N (%) | 38 |
| Noncomplex karyotype (<3 aberrations), n (%) | 19 (50.0) |
| Complex karyotype (≥3 aberrations), n (%) | 19 (50.0) |
| CLL-IPI risk group, N (%) | 39 |
| Low, n (%) | 2 (5.1) |
| Intermediate, n (%) | 6 (15.4) |
| High, n (%) | 18 (46.2) |
| Very high, n (%) | 13 (33.3) |
| Previous lines of treatment | 40 |
| Median (range) | 1 (1-5) |
| Previous treatment with venetoclax, N (%) | 40 |
| Yes, n (%) | 7 (17.5) |
| Previous treatment with a BTKi, N (%) | 40 |
| Yes, n (%) | 18 (45.0) |
| Previous treatment with a BTKi and venetoclax, N (%) | 40 |
| Yes, n (%) | 5 (12.5) |
| Previous treatment with a BTKi and/or venetoclax, N (%) | 40 |
| Yes, n (%) | 20 (50.0) |
| Characteristics . | Full analysis set . |
|---|---|
| All patients of the full analysis set, N | 40 |
| Sex, N (%) | 40 |
| Female, n (%) | 13 (32.5) |
| Male, n (%) | 27 (67.5) |
| Age, y | 40 |
| Median (range) | 64 (40-82) |
| Time since first diagnosis, mo | 40 |
| Median (range) | 103.5 (42.2-240.2) |
| Binet stage, N (%) | 40 |
| A, n (%) | 11 (27.5) |
| B, n (%) | 19 (47.5) |
| C, n (%) | 10 (25.0) |
| Total CIRS score | 40 |
| Median (range) | 3 (0-12) |
| Creatinine clearance (mL/min) | 40 |
| Median (range) | 82.1 (35.6-153.1) |
| del(17p), N (%) | 40 |
| Yes, n (%) | 5 (12.5) |
| del(11q), N (%) | 40 |
| Yes, n (%) | 15 (37.5) |
| Trisomy 12, N (%) | 40 |
| Yes, n (%) | 3 (7.5) |
| del(13q), N (%) | 40 |
| Yes, n (%) | 23 (57.5) |
| Type according to hierarchical model, N (%) | 40 |
| del(17p), n (%) | 5 (12.5) |
| del(11q), n (%) | 15 (37.5) |
| Trisomy 12, n (%) | 1 (2.5) |
| Not del(17p)/del(11q)/trisomy 12/del(13q), n (%) | 9 (22.5) |
| del(13q) alone, n (%) | 10 (25.0) |
| IGHV mutational status, N (%) | 40 |
| Unmutated, n (%) | 31 (77.5) |
| Mutated, n (%) | 9 (22.5) |
| TP53 mutational status, N (%) | 40 |
| Unmutated, n (%) | 26 (65.0) |
| Mutated, n (%) | 14 (35.0) |
| TP53 status, N (%) | 40 |
| None, n (%) | 25 (62.5) |
| Deleted and/or mutated, n (%) | 15 (37.5) |
| NOTCH1 mutational status, N (%) | 40 |
| Unmutated, n (%) | 30 (75.0) |
| Mutated, n (%) | 10 (25.0) |
| SF3B1 mutational status, N (%) | 40 |
| Unmutated, n (%) | 27 (67.5) |
| Mutated, n (%) | 13 (32.5) |
| Serum β2-microglobulin (mg/dL) | 39 |
| Median (range) | 4.5 (2.1-17.2) |
| Complex karyotype, N (%) | 38 |
| Noncomplex karyotype (<3 aberrations), n (%) | 19 (50.0) |
| Complex karyotype (≥3 aberrations), n (%) | 19 (50.0) |
| CLL-IPI risk group, N (%) | 39 |
| Low, n (%) | 2 (5.1) |
| Intermediate, n (%) | 6 (15.4) |
| High, n (%) | 18 (46.2) |
| Very high, n (%) | 13 (33.3) |
| Previous lines of treatment | 40 |
| Median (range) | 1 (1-5) |
| Previous treatment with venetoclax, N (%) | 40 |
| Yes, n (%) | 7 (17.5) |
| Previous treatment with a BTKi, N (%) | 40 |
| Yes, n (%) | 18 (45.0) |
| Previous treatment with a BTKi and venetoclax, N (%) | 40 |
| Yes, n (%) | 5 (12.5) |
| Previous treatment with a BTKi and/or venetoclax, N (%) | 40 |
| Yes, n (%) | 20 (50.0) |
CIRS, cumulative illness rating scale; IGHV, immunoglobulin heavy chain variable region gene; IPI, International Prognostic Index.